Immune-resistant mechanisms in cancer immunotherapy

Yutaka Kawakami, Shigeki Ohta, Mohammad A. Sayem, Nobuo Tsukamoto, Tomonori Yaguchi

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)


Immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 antibodies (Abs) and CTLA4 Abs and T cell-based adoptive cell therapies are effective for patients with various cancers. However, response rates of ICI monotherapies are still limited due to lack of immunogenic antigens and various immune-resistant mechanisms. The latter includes adaptive immune resistance that is caused by anti-tumor T cells (e.g. PD-L1 induced by IFN-γ from T cells) and primary immune resistance that is caused by cancer cells (e.g. immunosuppressive cytokines produced by cancer cells). Further understanding of the immune-resistant mechanisms, which may be possible through comparative analyses of responders and non-responders to the immunotherapies, will lead to the identification of new diagnostic biomarkers and therapeutic targets for development of effective cancer immuno therapies.

Original languageEnglish
Pages (from-to)810-817
Number of pages8
JournalInternational Journal of Clinical Oncology
Issue number5
Publication statusPublished - 2020 May 1


  • Immune checkpoint inhibitor
  • Immunometabolism
  • Microbiota
  • Neo-antigen
  • Oncogene
  • TGF-β

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Immune-resistant mechanisms in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this